{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T11:09:30Z","timestamp":1785409770276,"version":"3.56.0"},"reference-count":251,"publisher":"MDPI AG","issue":"7","license":[{"start":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T00:00:00Z","timestamp":1784592000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["No. 32573409, No. 32172839"],"award-info":[{"award-number":["No. 32573409, No. 32172839"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"award":["No. 32573409, No. 32172839"],"award-info":[{"award-number":["No. 32573409, No. 32172839"]}],"id":[{"id":"https:\/\/ror.org\/01h0zpd94","id-type":"ROR","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100006407","name":"Natural Science Foundation of Henan","doi-asserted-by":"crossref","award":["No. 252300423606"],"award-info":[{"award-number":["No. 252300423606"]}],"id":[{"id":"10.13039\/501100006407","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Viruses"],"abstract":"<jats:p>Coronaviruses (family Coronaviridae) are enveloped, positive-sense, single-stranded RNA viruses with broad host adaptability. They transmit across species among humans, livestock, companion animals, and wildlife, eliciting a disease spectrum ranging from mild respiratory and gastrointestinal symptoms to fatal multi-organ failure, thereby posing significant challenges to global health. In this context, drug repurposing has emerged as a practical strategy for rapidly identifying broad-spectrum antivirals against emerging and re-emerging coronaviruses. Using coronaviruses as a paradigm, this review systematically summarizes research advances and mechanistic insights into the repurposing of existing drugs against coronaviruses. Simultaneously, we dissect core challenges including species-specific pharmacokinetic disparities, insufficient inter-genera conservation of viral targets, and systemic barriers between human and veterinary drug regulatory frameworks and propose innovative solutions encompassing AI-driven cross-species drug prediction, next-generation cross-species infection models, and a \u201chuman-veterinary dual-track\u201d collaborative research and development system. Collectively, this review highlights the promise of drug repurposing as a broad-spectrum antiviral strategy and provides a translational perspective for the development of cross-species anti-coronavirus therapeutics.<\/jats:p>","DOI":"10.3390\/v18070804","type":"journal-article","created":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T16:16:39Z","timestamp":1784650599000},"page":"804","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Drug Repurposing as a Broad-Spectrum Strategy Against Coronaviruses: Frontiers in Mechanisms and Clinical Translation"],"prefix":"10.3390","volume":"18","author":[{"given":"Shuai","family":"Du","sequence":"first","affiliation":[{"name":"College of Veterinary Medicine, Henan Agricultural University, Zhengzhou 450046, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yue","family":"Wang","sequence":"additional","affiliation":[{"name":"College of Veterinary Medicine, Henan Agricultural University, Zhengzhou 450046, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chao","family":"Liu","sequence":"additional","affiliation":[{"name":"College of Veterinary Medicine, Henan Agricultural University, Zhengzhou 450046, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yiming","family":"Han","sequence":"additional","affiliation":[{"name":"College of Veterinary Medicine, Henan Agricultural University, Zhengzhou 450046, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rui","family":"Zong","sequence":"additional","affiliation":[{"name":"College of Veterinary Medicine, Henan Agricultural University, Zhengzhou 450046, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shen","family":"Wang","sequence":"additional","affiliation":[{"name":"College of Veterinary Medicine, Henan Agricultural University, Zhengzhou 450046, China"},{"name":"International Joint Research Center of National Animal Immunology, College of Veterinary Medicine, Henan Agricultural University, Zhengzhou 450046, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenjuan","family":"Du","sequence":"additional","affiliation":[{"name":"College of Veterinary Medicine, Henan Agricultural University, Zhengzhou 450046, China"},{"name":"International Joint Research Center of National Animal Immunology, College of Veterinary Medicine, Henan Agricultural University, Zhengzhou 450046, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8740-1795","authenticated-orcid":false,"given":"Linyang","family":"Yu","sequence":"additional","affiliation":[{"name":"College of Veterinary Medicine, Henan Agricultural University, Zhengzhou 450046, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3264-2991","authenticated-orcid":false,"given":"Yongtao","family":"Li","sequence":"additional","affiliation":[{"name":"College of Veterinary Medicine, Henan Agricultural University, Zhengzhou 450046, China"},{"name":"International Joint Research Center of National Animal Immunology, College of Veterinary Medicine, Henan Agricultural University, Zhengzhou 450046, China"},{"name":"Ministry of Education Key Laboratory for Animal Pathogens and Biosafety, Henan Agricultural University, Zhengzhou 450046, China"},{"name":"Longhu Laboratory of Advanced Immunology, Zhengzhou 450046, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,7,21]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0065-3527(08)60286-9","article-title":"The molecular biology of coronaviruses","volume":"48","author":"Lai","year":"1997","journal-title":"Adv. Virus Res."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"001843","DOI":"10.1099\/jgv.0.001843","article-title":"ICTV Virus Taxonomy Profile: Coronaviridae 2023","volume":"104","author":"Woo","year":"2023","journal-title":"J. Gen. Virol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1002\/jmv.25685","article-title":"Coronavirus infections and immune responses","volume":"92","author":"Li","year":"2020","journal-title":"J. Med. Virol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1186\/s44149-021-00005-9","article-title":"The taxonomy, host range and pathogenicity of coronaviruses and other viruses in the Nidovirales order","volume":"1","author":"Zhou","year":"2021","journal-title":"Anim. Dis."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"e2282","DOI":"10.1002\/rmv.2282","article-title":"An overview on the seven pathogenic human coronaviruses","volume":"32","author":"Kesheh","year":"2022","journal-title":"Rev. Med. Virol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1016\/j.tim.2016.03.003","article-title":"Epidemiology, Genetic Recombination, and Pathogenesis of Coronaviruses","volume":"24","author":"Su","year":"2016","journal-title":"Trends Microbiol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1001\/jama.2020.12839","article-title":"Pathophysiology, Transmission, Diagnosis, and Treatment of Coronavirus Disease 2019 (COVID-19): A Review","volume":"324","author":"Wiersinga","year":"2020","journal-title":"Jama"},{"key":"ref_8","doi-asserted-by":"crossref","unstructured":"Lin, C.N., Chan, K.R., Ooi, E.E., Chiou, M.T., Hoang, M., Hsueh, P.R., and Ooi, P.T. (2021). Animal Coronavirus Diseases: Parallels with COVID-19 in Humans. Viruses, 13.","DOI":"10.3390\/v13081507"},{"key":"ref_9","doi-asserted-by":"crossref","unstructured":"Nova, N. (2021). Cross-Species Transmission of Coronaviruses in Humans and Domestic Mammals, What Are the Ecological Mechanisms Driving Transmission, Spillover, and Disease Emergence?. Front. Public Health, 9.","DOI":"10.3389\/fpubh.2021.717941"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1811","DOI":"10.1007\/s00705-021-05008-y","article-title":"Research progress on coronavirus S proteins and their receptors","volume":"166","author":"Yuan","year":"2021","journal-title":"Arch. Virol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"15092","DOI":"10.1038\/ncomms15092","article-title":"Cryo-EM structures of MERS-CoV and SARS-CoV spike glycoproteins reveal the dynamic receptor binding domains","volume":"8","author":"Yuan","year":"2017","journal-title":"Nat. Commun."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1146\/annurev-virology-110615-042301","article-title":"Structure, Function, and Evolution of Coronavirus Spike Proteins","volume":"3","author":"Li","year":"2016","journal-title":"Annu. Rev. Virol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/bs.aivir.2016.08.004","article-title":"Coronavirus Spike Protein and Tropism Changes","volume":"96","author":"Hulswit","year":"2016","journal-title":"Adv. Virus Res."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/bs.aivir.2016.08.001","article-title":"Viral and Cellular mRNA Translation in Coronavirus-Infected Cells","volume":"96","author":"Nakagawa","year":"2016","journal-title":"Adv. Virus Res."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1016\/0092-8674(89)90124-4","article-title":"Characterization of an efficient coronavirus ribosomal frameshifting signal: Requirement for an RNA pseudoknot","volume":"57","author":"Brierley","year":"1989","journal-title":"Cell"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/978-1-4939-2438-7_1","article-title":"Coronaviruses: An overview of their replication and pathogenesis","volume":"1282","author":"Fehr","year":"2015","journal-title":"Methods Mol. Biol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"2991","DOI":"10.3390\/v6082991","article-title":"The coronavirus nucleocapsid is a multifunctional protein","volume":"6","author":"McBride","year":"2014","journal-title":"Viruses"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"2716","DOI":"10.1021\/acs.jmedchem.0c01140","article-title":"Targeting SARS-CoV-2 Proteases and Polymerase for COVID-19 Treatment: State of the Art and Future Opportunities","volume":"65","author":"Cannalire","year":"2022","journal-title":"J. Med. Chem."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"4122","DOI":"10.1128\/JVI.02232-10","article-title":"Evidence that TMPRSS2 activates the severe acute respiratory syndrome coronavirus spike protein for membrane fusion and reduces viral control by the humoral immune response","volume":"85","author":"Glowacka","year":"2011","journal-title":"J. Virol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1965","DOI":"10.1002\/med.21783","article-title":"What coronavirus 3C-like protease tells us: From structure, substrate selectivity, to inhibitor design","volume":"41","author":"Xiong","year":"2021","journal-title":"Med. Res. Rev."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"5871","DOI":"10.1021\/acscatal.0c00110","article-title":"Comprehensive Insights into the Catalytic Mechanism of Middle East Respiratory Syndrome 3C-Like Protease and Severe Acute Respiratory Syndrome 3C-Like Protease","volume":"10","author":"Wang","year":"2020","journal-title":"ACS Catal."},{"key":"ref_22","first-page":"100100","article-title":"Immune evasion strategies of Seneca Valley virus: Mechanisms of host innate immune suppression","volume":"3","author":"Xie","year":"2025","journal-title":"Agric. Commun."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1126\/science.abb7498","article-title":"Structure of the RNA-dependent RNA polymerase from COVID-19 virus","volume":"368","author":"Gao","year":"2020","journal-title":"Science"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"104793","DOI":"10.1016\/j.antiviral.2020.104793","article-title":"Remdesivir and SARS-CoV-2: Structural requirements at both nsp12 RdRp and nsp14 Exonuclease active-sites","volume":"178","author":"Shannon","year":"2020","journal-title":"Antivir. Res."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1038\/s41467-021-21060-3","article-title":"Structure of papain-like protease from SARS-CoV-2 and its complexes with non-covalent inhibitors","volume":"12","author":"Osipiuk","year":"2021","journal-title":"Nat. Commun."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1080\/22221751.2021.1888660","article-title":"The in vitro antiviral activity of lactoferrin against common human coronaviruses and SARS-CoV-2 is mediated by targeting the heparan sulfate co-receptor","volume":"10","author":"Hu","year":"2021","journal-title":"Emerg. Microbes Infect."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"2070","DOI":"10.1038\/s41467-020-16048-4","article-title":"Neutralization of SARS-CoV-2 spike pseudotyped virus by recombinant ACE2-Ig","volume":"11","author":"Lei","year":"2020","journal-title":"Nat. Commun."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/j.cell.2020.02.052","article-title":"SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor","volume":"181","author":"Hoffmann","year":"2020","journal-title":"Cell"},{"key":"ref_29","first-page":"E5135","article-title":"Broad receptor engagement of an emerging global coronavirus may potentiate its diverse cross-species transmissibility","volume":"115","author":"Li","year":"2018","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"3134","DOI":"10.1128\/JVI.01394-09","article-title":"Recombination, reservoirs, and the modular spike: Mechanisms of coronavirus cross-species transmission","volume":"84","author":"Graham","year":"2010","journal-title":"J. Virol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1126\/science.1087139","article-title":"Isolation and characterization of viruses related to the SARS coronavirus from animals in southern China","volume":"302","author":"Guan","year":"2003","journal-title":"Science"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"2001","DOI":"10.1128\/JVI.79.4.2001-2009.2005","article-title":"Identification of a novel coronavirus in bats","volume":"79","author":"Poon","year":"2005","journal-title":"J. Virol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1126\/science.1118391","article-title":"Bats are natural reservoirs of SARS-like coronaviruses","volume":"310","author":"Li","year":"2005","journal-title":"Science"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1016\/S1473-3099(13)70164-6","article-title":"Middle East respiratory syndrome coronavirus neutralising serum antibodies in dromedary camels: A comparative serological study","volume":"13","author":"Reusken","year":"2013","journal-title":"Lancet Infect. Dis."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1128\/CMR.00102-14","article-title":"Middle East respiratory syndrome coronavirus: Another zoonotic betacoronavirus causing SARS-like disease","volume":"28","author":"Chan","year":"2015","journal-title":"Clin. Microbiol. Rev."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"1339","DOI":"10.3201\/eid2008.140663","article-title":"Isolation of MERS coronavirus from a dromedary camel, Qatar, 2014","volume":"20","author":"Raj","year":"2014","journal-title":"Emerg. Infect. Dis."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1038\/s41586-020-2012-7","article-title":"A pneumonia outbreak associated with a new coronavirus of probable bat origin","volume":"579","author":"Zhou","year":"2020","journal-title":"Nature"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1038\/s41586-020-2169-0","article-title":"Identifying SARS-CoV-2-related coronaviruses in Malayan pangolins","volume":"583","author":"Lam","year":"2020","journal-title":"Nature"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1038\/s41586-018-0010-9","article-title":"Fatal swine acute diarrhoea syndrome caused by an HKU2-related coronavirus of bat origin","volume":"556","author":"Zhou","year":"2018","journal-title":"Nature"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"465","DOI":"10.2478\/jvetres-2019-0064","article-title":"Current Status of Porcine Epidemic Diarrhoea (PED) in European Pigs","volume":"63","author":"Antas","year":"2019","journal-title":"J. Vet. Res."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1177\/1098612X221118761","article-title":"2022 AAFP\/EveryCat Feline Infectious Peritonitis Diagnosis Guidelines","volume":"24","author":"Thayer","year":"2022","journal-title":"J. Feline Med. Surg."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"001828","DOI":"10.1099\/jmm.0.001828","article-title":"Infectious bronchitis virus: An overview of the \u201cchicken coronavirus\u201d","volume":"73","author":"Falchieri","year":"2024","journal-title":"J. Med. Microbiol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1038\/s41586-021-04111-z","article-title":"Independent infections of porcine deltacoronavirus among Haitian children","volume":"600","author":"Lednicky","year":"2021","journal-title":"Nature"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1093\/cid\/ciab456","article-title":"Novel Canine Coronavirus Isolated from a Hospitalized Patient With Pneumonia in East Malaysia","volume":"74","author":"Vlasova","year":"2022","journal-title":"Clin. Infect. Dis."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"1729","DOI":"10.1016\/j.cell.2025.01.042","article-title":"Bat-infecting merbecovirus HKU5-CoV lineage 2 can use human ACE2 as a cell entry receptor","volume":"188","author":"Chen","year":"2025","journal-title":"Cell"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"100172","DOI":"10.1016\/j.vetvac.2026.100172","article-title":"The epidemiological and evolutionary dynamics of Getah virus in China","volume":"5","author":"Yu","year":"2026","journal-title":"Vet. Vaccine"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1038\/s41577-020-00479-7","article-title":"A guide to vaccinology: From basic principles to new developments","volume":"21","author":"Pollard","year":"2021","journal-title":"Nat. Rev. Immunol."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"100158","DOI":"10.1016\/j.vetvac.2026.100158","article-title":"Current landscape and domestic breakthroughs: A comprehensive review of pet vaccines in China","volume":"5","author":"Zhang","year":"2026","journal-title":"Vet. Vaccine"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.jhealeco.2016.01.012","article-title":"Innovation in the pharmaceutical industry: New estimates of R&D costs","volume":"47","author":"DiMasi","year":"2016","journal-title":"J. Health Econ."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1038\/nrd1468","article-title":"Drug repositioning: Identifying and developing new uses for existing drugs","volume":"3","author":"Ashburn","year":"2004","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1038\/nrd.2018.168","article-title":"Drug repurposing: Progress, challenges and recommendations","volume":"18","author":"Pushpakom","year":"2019","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"2076","DOI":"10.1016\/j.drudis.2019.06.014","article-title":"Drug repurposing: A promising tool to accelerate the drug discovery process","volume":"24","author":"Parvathaneni","year":"2019","journal-title":"Drug Discov. Today"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"43395","DOI":"10.1038\/srep43395","article-title":"GS-5734 and its parent nucleoside analog inhibit Filo-, Pneumo-, and Paramyxoviruses","volume":"7","author":"Lo","year":"2017","journal-title":"Sci. Rep."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"6785","DOI":"10.1074\/jbc.RA120.013679","article-title":"Remdesivir is a direct-acting antiviral that inhibits RNA-dependent RNA polymerase from severe acute respiratory syndrome coronavirus 2 with high potency","volume":"295","author":"Gordon","year":"2020","journal-title":"J. Biol. Chem."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.1056\/NEJMoa2007764","article-title":"Remdesivir for the Treatment of COVID-19\u2014Final Report","volume":"383","author":"Beigel","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/j.cell.2020.02.058","article-title":"Structure, Function, and Antigenicity of the SARS-CoV-2 Spike Glycoprotein","volume":"181","author":"Walls","year":"2020","journal-title":"Cell"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"fuaa057","DOI":"10.1093\/femsre\/fuaa057","article-title":"Molecular diversity of coronavirus host cell entry receptors","volume":"45","author":"Millet","year":"2021","journal-title":"FEMS Microbiol. Rev."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1038\/s41586-022-05594-0","article-title":"FXR inhibition may protect from SARS-CoV-2 infection by reducing ACE2","volume":"615","author":"Brevini","year":"2023","journal-title":"Nature"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1111\/joim.13630","article-title":"Ursodeoxycholic acid is associated with a reduction in SARS-CoV-2 infection and reduced severity of COVID-19 in patients with cirrhosis","volume":"293","author":"John","year":"2023","journal-title":"J. Intern. Med."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"e0363325","DOI":"10.1128\/spectrum.03633-25","article-title":"Ursodeoxycholic acid inhibits feline infectious peritonitis virus infection through activating JAK-STAT signaling pathway-induced type I interferon","volume":"14","author":"Zhong","year":"2026","journal-title":"Microbiol. Spectr."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1186\/s13567-026-01721-1","article-title":"Ursodeoxycholic acid inhibits pneumonia caused by PRCV through the activation of TLR4-IRF3 mediated type I interferon pathway","volume":"57","author":"Zhang","year":"2026","journal-title":"Vet. Res."},{"key":"ref_62","doi-asserted-by":"crossref","unstructured":"Lang, J., Yang, N., Deng, J., Liu, K., Yang, P., Zhang, G., and Jiang, C. (2011). Inhibition of SARS pseudovirus cell entry by lactoferrin binding to heparan sulfate proteoglycans. PLoS ONE, 6.","DOI":"10.1371\/journal.pone.0023710"},{"key":"ref_63","doi-asserted-by":"crossref","unstructured":"Miotto, M., Di Rienzo, L., B\u00f2, L., Boffi, A., Ruocco, G., and Milanetti, E. (2021). Molecular Mechanisms Behind Anti SARS-CoV-2 Action of Lactoferrin. Front. Mol. Biosci., 8.","DOI":"10.3389\/fmolb.2021.607443"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"e28281","DOI":"10.1002\/jmv.28281","article-title":"Bovine lactoferrin inhibits SARS-CoV-2 and SARS-CoV-1 by targeting the RdRp complex and alleviates viral infection in the hamster model","volume":"95","author":"He","year":"2023","journal-title":"J. Med. Virol."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1186\/s13567-025-01456-5","article-title":"Lactoferrin exhibits PEDV antiviral activity by interfering with spike-heparan sulfate proteoglycans binding and activating mucosal immune response","volume":"56","author":"Liu","year":"2025","journal-title":"Vet. Res."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"106118","DOI":"10.1016\/j.ijantimicag.2020.106118","article-title":"Lactoferrin as potential preventative and adjunct treatment for COVID-19","volume":"56","author":"Chang","year":"2020","journal-title":"Int. J. Antimicrob. Agents"},{"key":"ref_67","doi-asserted-by":"crossref","unstructured":"Campione, E., Cosio, T., Rosa, L., Lanna, C., Di Girolamo, S., Gaziano, R., Valenti, P., and Bianchi, L. (2020). Lactoferrin as Protective Natural Barrier of Respiratory and Intestinal Mucosa against Coronavirus Infection and Inflammation. Int. J. Mol. Sci., 21.","DOI":"10.3390\/ijms21144903"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"4873","DOI":"10.1111\/bph.15166","article-title":"Statins: Could an old friend help in the fight against COVID-19?","volume":"177","author":"Marchant","year":"2020","journal-title":"Br. J. Pharmacol."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.biochi.2021.06.005","article-title":"Coronaviruses, cholesterol and statins: Involvement and application for COVID-19","volume":"189","author":"Orlowski","year":"2021","journal-title":"Biochimie"},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1016\/j.cmet.2020.06.015","article-title":"In-Hospital Use of Statins Is Associated with a Reduced Risk of Mortality among Individuals with COVID-19","volume":"32","author":"Zhang","year":"2020","journal-title":"Cell Metab."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.1038\/s41467-021-21553-1","article-title":"Association between antecedent statin use and decreased mortality in hospitalized patients with COVID-19","volume":"12","author":"Gupta","year":"2021","journal-title":"Nat. Commun."},{"key":"ref_72","doi-asserted-by":"crossref","unstructured":"Sorice, M., Misasi, R., Riitano, G., Manganelli, V., Martellucci, S., Longo, A., Garofalo, T., and Mattei, V. (2020). Targeting Lipid Rafts as a Strategy Against Coronavirus. Front. Cell Dev. Biol., 8.","DOI":"10.3389\/fcell.2020.618296"},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1099\/vir.0.070870-0","article-title":"Role of the lipid rafts in the life cycle of canine coronavirus","volume":"96","author":"Pratelli","year":"2015","journal-title":"J. Gen. Virol."},{"key":"ref_74","doi-asserted-by":"crossref","unstructured":"Dai, J., Wang, H., Liao, Y., Tan, L., Sun, Y., Song, C., Liu, W., Qiu, X., and Ding, C. (2022). Coronavirus Infection and Cholesterol Metabolism. Front. Immunol., 13.","DOI":"10.3389\/fimmu.2022.791267"},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"114997","DOI":"10.1016\/j.biopha.2023.114997","article-title":"\u03b2-Cyclodextrins as affordable antivirals to treat coronavirus infection","volume":"164","author":"Tenorio","year":"2023","journal-title":"Biomed. Pharmacother."},{"key":"ref_76","doi-asserted-by":"crossref","unstructured":"Alboni, S., Secco, V., Papotti, B., Vilella, A., Adorni, M.P., Zimetti, F., Schaeffer, L., Tascedda, F., Zoli, M., and Leblanc, P. (2023). Hydroxypropyl-\u03b2-Cyclodextrin Depletes Membrane Cholesterol and Inhibits SARS-CoV-2 Entry into HEK293T-ACE(hi) Cells. Pathogens, 12.","DOI":"10.3390\/pathogens12050647"},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"115057","DOI":"10.1016\/j.jpba.2022.115057","article-title":"A novel and water-soluble material for coronavirus inactivation from oseltamivir in the cavity of methyl and sulfated-\u03b2-cyclodextrins through inclusion complexation","volume":"221","author":"Rajamohan","year":"2022","journal-title":"J. Pharm. Biomed. Anal."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1038\/s41421-020-0156-0","article-title":"Hydroxychloroquine, a less toxic derivative of chloroquine, is effective in inhibiting SARS-CoV-2 infection in vitro","volume":"6","author":"Liu","year":"2020","journal-title":"Cell Discov."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1093\/cid\/ciaa237","article-title":"In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)","volume":"71","author":"Yao","year":"2020","journal-title":"Clin. Infect. Dis."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"105960","DOI":"10.1016\/j.ijantimicag.2020.105960","article-title":"Structural and molecular modelling studies reveal a new mechanism of action of chloroquine and hydroxychloroquine against SARS-CoV-2 infection","volume":"55","author":"Fantini","year":"2020","journal-title":"Int. J. Antimicrob. Agents"},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/j.antiviral.2013.04.016","article-title":"Effect of chloroquine on feline infectious peritonitis virus infection in vitro and in vivo","volume":"99","author":"Takano","year":"2013","journal-title":"Antivir. Res."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1016\/j.vetmic.2014.10.030","article-title":"Identification and characterisation of small molecule inhibitors of feline coronavirus replication","volume":"174","author":"McDonagh","year":"2014","journal-title":"Vet. Microbiol."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"2030","DOI":"10.1056\/NEJMoa2022926","article-title":"Effect of Hydroxychloroquine in Hospitalized Patients with COVID-19","volume":"383","author":"Horby","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"2165","DOI":"10.1001\/jama.2020.22240","article-title":"Effect of Hydroxychloroquine on Clinical Status at 14 Days in Hospitalized Patients With COVID-19: A Randomized Clinical Trial","volume":"324","author":"Self","year":"2020","journal-title":"Jama"},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"287","DOI":"10.7326\/M20-2496","article-title":"Hydroxychloroquine or Chloroquine for Treatment or Prophylaxis of COVID-19: A Living Systematic Review","volume":"173","author":"Hernandez","year":"2020","journal-title":"Ann. Intern. Med."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1016\/j.thromres.2020.09.026","article-title":"Therapeutic versus prophylactic anticoagulation for severe COVID-19: A randomized phase II clinical trial (HESACOVID)","volume":"196","author":"Lemos","year":"2020","journal-title":"Thromb. Res."},{"key":"ref_87","doi-asserted-by":"crossref","unstructured":"Ennemoser, M., Rieger, J., Muttenthaler, E., Gerlza, T., Zatloukal, K., and Kungl, A.J. (2021). Enoxaparin and Pentosan Polysulfate Bind to the SARS-CoV-2 Spike Protein and Human ACE2 Receptor, Inhibiting Vero Cell Infection. Biomedicines, 10.","DOI":"10.3390\/biomedicines10010049"},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"5207","DOI":"10.1038\/s41598-022-09133-9","article-title":"Enoxaparin augments alpha-1-antitrypsin inhibition of TMPRSS2, a promising drug combination against COVID-19","volume":"12","author":"Bai","year":"2022","journal-title":"Sci. Rep."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"105606","DOI":"10.1016\/j.antiviral.2023.105606","article-title":"Omicsynin B4 potently blocks coronavirus infection by inhibiting host proteases cathepsin L and TMPRSS2","volume":"214","author":"Li","year":"2023","journal-title":"Antivir. Res."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1111\/bcpt.13533","article-title":"Camostat mesylate against SARS-CoV-2 and COVID-19-Rationale, dosing and safety","volume":"128","author":"Breining","year":"2021","journal-title":"Basic. Clin. Pharmacol. Toxicol."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"103255","DOI":"10.1016\/j.ebiom.2021.103255","article-title":"Camostat mesylate inhibits SARS-CoV-2 activation by TMPRSS2-related proteases and its metabolite GBPA exerts antiviral activity","volume":"65","author":"Hoffmann","year":"2021","journal-title":"EBioMedicine"},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"100597","DOI":"10.1016\/j.imu.2021.100597","article-title":"Structural insights and inhibition mechanism of TMPRSS2 by experimentally known inhibitors Camostat mesylate, Nafamostat and Bromhexine hydrochloride to control SARS-coronavirus-2: A molecular modeling approach","volume":"24","author":"Sonawane","year":"2021","journal-title":"Inf. Med. Unlocked"},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"e0086121","DOI":"10.1128\/JVI.00861-21","article-title":"Structural Basis of Covalent Inhibitory Mechanism of TMPRSS2-Related Serine Proteases by Camostat","volume":"95","author":"Sun","year":"2021","journal-title":"J. Virol."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"12552","DOI":"10.1128\/JVI.01890-13","article-title":"Middle East respiratory syndrome coronavirus infection mediated by the transmembrane serine protease TMPRSS2","volume":"87","author":"Shirato","year":"2013","journal-title":"J. Virol."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"100849","DOI":"10.1016\/j.eclinm.2021.100849","article-title":"Efficacy of the TMPRSS2 inhibitor camostat mesilate in patients hospitalized with COVID-19-a double-blind randomized controlled trial","volume":"35","author":"Gunst","year":"2021","journal-title":"EClinicalMedicine"},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1007\/s00134-021-06395-1","article-title":"Camostat mesylate therapy in critically ill patients with COVID-19 pneumonia","volume":"47","author":"Sakr","year":"2021","journal-title":"Intensive Care Med."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1080\/21505594.2020.1770491","article-title":"Establishment of stable Vero cell lines expressing TMPRSS2 and MSPL: A useful tool for propagating porcine epidemic diarrhea virus in the absence of exogenous trypsin","volume":"11","author":"Wang","year":"2020","journal-title":"Virulence"},{"key":"ref_98","doi-asserted-by":"crossref","unstructured":"Shi, W., Fan, W., Bai, J., Tang, Y., Wang, L., Jiang, Y., Tang, L., Liu, M., Cui, W., and Xu, Y. (2017). TMPRSS2 and MSPL Facilitate Trypsin-Independent Porcine Epidemic Diarrhea Virus Replication in Vero Cells. Viruses, 9.","DOI":"10.3390\/v9050114"},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"106004","DOI":"10.1016\/j.ijantimicag.2020.106004","article-title":"Amantadine disrupts lysosomal gene expression: A hypothesis for COVID19 treatment","volume":"55","author":"Smieszek","year":"2020","journal-title":"Int. J. Antimicrob. Agents"},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"1402","DOI":"10.1038\/s42003-021-02940-2","article-title":"Author Correction: Amantadine inhibits known and novel ion channels encoded by SARS-CoV-2 in vitro","volume":"4","author":"Jeppesen","year":"2021","journal-title":"Commun. Biol."},{"key":"ref_101","doi-asserted-by":"crossref","unstructured":"Fink, K., Nitsche, A., Neumann, M., Grossegesse, M., Eisele, K.H., and Danysz, W. (2021). Amantadine Inhibits SARS-CoV-2 In Vitro. Viruses, 13.","DOI":"10.3390\/v13040539"},{"key":"ref_102","doi-asserted-by":"crossref","unstructured":"Zhou, Y., Gammeltoft, K.A., Galli, A., Offersgaard, A., Fahn\u00f8e, U., Ramirez, S., Bukh, J., and Gottwein, J.M. (2021). Efficacy of Ion-Channel Inhibitors Amantadine, Memantine and Rimantadine for the Treatment of SARS-CoV-2 In Vitro. Viruses, 13.","DOI":"10.3390\/v13102082"},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"e2310306","DOI":"10.1002\/adma.202310306","article-title":"Nanoengineered Red Blood Cells Loaded with TMPRSS2 and Cathepsin L Inhibitors Block SARS-CoV-2 Pseudovirus Entry into Lung ACE2(+) Cells","volume":"36","author":"Yang","year":"2024","journal-title":"Adv. Mater."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1006\/viro.1995.1123","article-title":"Coronavirus protein processing and RNA synthesis is inhibited by the cysteine proteinase inhibitor E64d","volume":"208","author":"Kim","year":"1995","journal-title":"Virology"},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1080\/13543776.2021.1857726","article-title":"Protease inhibitors targeting the main protease and papain-like protease of coronaviruses","volume":"31","author":"Capasso","year":"2021","journal-title":"Expert. Opin. Ther. Pat."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"6537","DOI":"10.1128\/JVI.00094-12","article-title":"Simultaneous treatment of human bronchial epithelial cells with serine and cysteine protease inhibitors prevents severe acute respiratory syndrome coronavirus entry","volume":"86","author":"Kawase","year":"2012","journal-title":"J. Virol."},{"key":"ref_107","doi-asserted-by":"crossref","unstructured":"Yamamoto, M., Kiso, M., Sakai-Tagawa, Y., Iwatsuki-Horimoto, K., Imai, M., Takeda, M., Kinoshita, N., Ohmagari, N., Gohda, J., and Semba, K. (2020). The Anticoagulant Nafamostat Potently Inhibits SARS-CoV-2 S Protein-Mediated Fusion in a Cell Fusion Assay System and Viral Infection In Vitro in a Cell-Type-Dependent Manner. Viruses, 12.","DOI":"10.3390\/v12060629"},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"6532","DOI":"10.1128\/AAC.01043-16","article-title":"Identification of Nafamostat as a Potent Inhibitor of Middle East Respiratory Syndrome Coronavirus S Protein-Mediated Membrane Fusion Using the Split-Protein-Based Cell-Cell Fusion Assay","volume":"60","author":"Yamamoto","year":"2016","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1039\/D0SC05064D","article-title":"Molecular mechanism of inhibiting the SARS-CoV-2 cell entry facilitator TMPRSS2 with camostat and nafamostat","volume":"12","author":"Hempel","year":"2021","journal-title":"Chem. Sci."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"e0097021","DOI":"10.1128\/mBio.00970-21","article-title":"The TMPRSS2 Inhibitor Nafamostat Reduces SARS-CoV-2 Pulmonary Infection in Mouse Models of COVID-19","volume":"12","author":"Li","year":"2021","journal-title":"mBio"},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"106922","DOI":"10.1016\/j.ijantimicag.2023.106922","article-title":"Antiviral effect and safety of nafamostat mesilate in patients with mild early-onset COVID-19: An exploratory multicentre randomized controlled clinical trial","volume":"62","author":"Okugawa","year":"2023","journal-title":"Int. J. Antimicrob. Agents"},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1038\/s41586-020-2368-8","article-title":"Structure of replicating SARS-CoV-2 polymerase","volume":"584","author":"Hillen","year":"2020","journal-title":"Nature"},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"1499","DOI":"10.1126\/science.abc1560","article-title":"Structural basis for inhibition of the RNA-dependent RNA polymerase from SARS-CoV-2 by remdesivir","volume":"368","author":"Yin","year":"2020","journal-title":"Science"},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"1548","DOI":"10.1016\/j.molcel.2021.01.035","article-title":"Remdesivir is a delayed translocation inhibitor of SARS-CoV-2 replication","volume":"81","author":"Bravo","year":"2021","journal-title":"Mol. Cell"},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1038\/s41594-021-00651-0","article-title":"Mechanism of molnupiravir-induced SARS-CoV-2 mutagenesis","volume":"28","author":"Kabinger","year":"2021","journal-title":"Nat. Struct. Mol. Biol."},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1016\/j.cell.2020.05.034","article-title":"Structural Basis for RNA Replication by the SARS-CoV-2 Polymerase","volume":"182","author":"Wang","year":"2020","journal-title":"Cell"},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1056\/NEJMoa2023184","article-title":"Repurposed Antiviral Drugs for COVID-19\u2014Interim WHO Solidarity Trial Results","volume":"384","author":"Pan","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.1016\/S0140-6736(20)31022-9","article-title":"Remdesivir in adults with severe COVID-19: A randomised, double-blind, placebo-controlled, multicentre trial","volume":"395","author":"Wang","year":"2020","journal-title":"Lancet"},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1177\/1098612X19825701","article-title":"Efficacy and safety of the nucleoside analog GS-441524 for treatment of cats with naturally occurring feline infectious peritonitis","volume":"21","author":"Pedersen","year":"2019","journal-title":"J. Feline Med. Surg."},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"1587","DOI":"10.1111\/jvim.15780","article-title":"Antiviral treatment using the adenosine nucleoside analogue GS-441524 in cats with clinically diagnosed neurological feline infectious peritonitis","volume":"34","author":"Dickinson","year":"2020","journal-title":"J. Vet. Intern. Med."},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"e21468","DOI":"10.1016\/j.heliyon.2023.e21468","article-title":"Remdesivir inhibits Porcine epidemic diarrhea virus infection in vitro","volume":"9","author":"Huang","year":"2023","journal-title":"Heliyon"},{"key":"ref_122","doi-asserted-by":"crossref","unstructured":"Dong, S., Sun, R., Chen, B., Si, F., Li, C., Zhang, D., Yu, R., and Liu, H. (2025). Porcine Epidemic Diarrhea Virus Is Inhibited by GS-441524 During an In Vitro Infection. Microorganisms, 13.","DOI":"10.3390\/microorganisms13051089"},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"e70186","DOI":"10.1002\/mco2.70186","article-title":"Broad-Spectrum Antiviral Activity of the Orally Bioavailable Antiviral ATV014 Against Multiple Coronaviruses","volume":"6","author":"Yang","year":"2025","journal-title":"MedComm"},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1038\/s41564-020-00835-2","article-title":"Therapeutically administered ribonucleoside analogue MK-4482\/EIDD-2801 blocks SARS-CoV-2 transmission in ferrets","volume":"6","author":"Cox","year":"2021","journal-title":"Nat. Microbiol."},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1056\/NEJMoa2116044","article-title":"Molnupiravir for Oral Treatment of COVID-19 in Nonhospitalized Patients","volume":"386","author":"Musungaie","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/S0140-6736(22)02597-1","article-title":"Molnupiravir plus usual care versus usual care alone as early treatment for adults with COVID-19 at increased risk of adverse outcomes (PANORAMIC): An open-label, platform-adaptive randomised controlled trial","volume":"401","author":"Butler","year":"2023","journal-title":"Lancet"},{"key":"ref_127","doi-asserted-by":"crossref","unstructured":"Huang, Z.X., Zhou, S.T., Yang, Z.B., and Wang, Z. (2023). Molnupiravir Inhibits Porcine Epidemic Diarrhea Virus Infection In Vitro. Viruses, 15.","DOI":"10.3390\/v15061317"},{"key":"ref_128","doi-asserted-by":"crossref","unstructured":"Doki, T., Shinohara, K., To, K., and Takano, T. (2025). Molnupiravir Inhibits Replication of Multiple Alphacoronavirus suis Strains in Feline Cells. Pathogens, 14.","DOI":"10.3390\/pathogens14080787"},{"key":"ref_129","doi-asserted-by":"crossref","unstructured":"Wang, R.R., Yang, Q.H., Luo, R.H., Peng, Y.M., Dai, S.X., Zhang, X.J., Chen, H., Cui, X.Q., Liu, Y.J., and Huang, J.F. (2014). Azvudine, a novel nucleoside reverse transcriptase inhibitor showed good drug combination features and better inhibition on drug-resistant strains than lamivudine in vitro. PLoS ONE, 9.","DOI":"10.1371\/journal.pone.0105617"},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1038\/s41392-021-00835-6","article-title":"Azvudine is a thymus-homing anti-SARS-CoV-2 drug effective in treating COVID-19 patients","volume":"6","author":"Zhang","year":"2021","journal-title":"Signal Transduct. Target. Ther."},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1038\/s41392-020-00351-z","article-title":"Azvudine (FNC): A promising clinical candidate for COVID-19 treatment","volume":"5","author":"Yu","year":"2020","journal-title":"Signal Transduct. Target. Ther."},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"e20153","DOI":"10.1016\/j.heliyon.2023.e20153","article-title":"Efficacy and safety of azvudine in patients with COVID-19: A systematic review and meta-analysis","volume":"9","author":"Chen","year":"2023","journal-title":"Heliyon"},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1038\/s41594-021-00570-0","article-title":"Structural basis for inhibition of the SARS-CoV-2 RNA polymerase by suramin","volume":"28","author":"Yin","year":"2021","journal-title":"Nat. Struct. Mol. Biol."},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1038\/s42003-023-04789-z","article-title":"Suramin binds and inhibits infection of SARS-CoV-2 through both spike protein-heparan sulfate and ACE2 receptor interactions","volume":"6","author":"Kwon","year":"2023","journal-title":"Commun. Biol."},{"key":"ref_135","doi-asserted-by":"crossref","unstructured":"Guo, C., Xu, H., Li, X., Yu, J., and Lin, D. (2023). Suramin Disturbs the Association of the N-Terminal Domain of SARS-CoV-2 Nucleocapsid Protein with RNA. Molecules, 28.","DOI":"10.3390\/molecules28062534"},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1126\/science.abb3405","article-title":"Crystal structure of SARS-CoV-2 main protease provides a basis for design of improved \u03b1-ketoamide inhibitors","volume":"368","author":"Zhang","year":"2020","journal-title":"Science"},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1038\/s41586-020-2223-y","article-title":"Structure of M(pro) from SARS-CoV-2 and discovery of its inhibitors","volume":"582","author":"Jin","year":"2020","journal-title":"Nature"},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1038\/s41586-020-2601-5","article-title":"Papain-like protease regulates SARS-CoV-2 viral spread and innate immunity","volume":"587","author":"Shin","year":"2020","journal-title":"Nature"},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"eadd0082","DOI":"10.1126\/scisignal.add0082","article-title":"The SARS-CoV-2 papain-like protease suppresses type I interferon responses by deubiquitinating STING","volume":"16","author":"Cao","year":"2023","journal-title":"Sci. Signal"},{"key":"ref_140","doi-asserted-by":"crossref","first-page":"2099","DOI":"10.1021\/acsinfecdis.0c00168","article-title":"Characterization and Noncovalent Inhibition of the Deubiquitinase and deISGylase Activity of SARS-CoV-2 Papain-Like Protease","volume":"6","author":"Freitas","year":"2020","journal-title":"ACS Infect. Dis."},{"key":"ref_141","doi-asserted-by":"crossref","first-page":"4282","DOI":"10.1038\/s41467-020-18096-2","article-title":"Feline coronavirus drug inhibits the main protease of SARS-CoV-2 and blocks virus replication","volume":"11","author":"Vuong","year":"2020","journal-title":"Nat. Commun."},{"key":"ref_142","doi-asserted-by":"crossref","first-page":"4417","DOI":"10.1038\/s41467-020-18233-x","article-title":"Both Boceprevir and GC376 efficaciously inhibit SARS-CoV-2 by targeting its main protease","volume":"11","author":"Fu","year":"2020","journal-title":"Nat. Commun."},{"key":"ref_143","doi-asserted-by":"crossref","first-page":"168474","DOI":"10.1016\/j.jmb.2024.168474","article-title":"Structural Basis for Coronaviral Main Proteases Inhibition by the 3CLpro Inhibitor GC376","volume":"436","author":"Lin","year":"2024","journal-title":"J. Mol. Biol."},{"key":"ref_144","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1038\/s41401-020-0483-6","article-title":"Anti-SARS-CoV-2 activities in vitro of Shuanghuanglian preparations and bioactive ingredients","volume":"41","author":"Su","year":"2020","journal-title":"Acta Pharmacol. Sin."},{"key":"ref_145","doi-asserted-by":"crossref","unstructured":"Mori, M., Quaglio, D., Calcaterra, A., Ghirga, F., Sorrentino, L., Cammarone, S., Fracella, M., D\u2019Auria, A., Frasca, F., and Criscuolo, E. (2023). Natural Flavonoid Derivatives Have Pan-Coronavirus Antiviral Activity. Microorganisms, 11.","DOI":"10.3390\/microorganisms11020314"},{"key":"ref_146","doi-asserted-by":"crossref","unstructured":"Li, Z., Zhu, L., Wang, L., Huang, Y., Zhang, Y., Zhao, D., Wang, L., Yi, D., Hou, Y., and Wu, T. (2024). Identification of two flavonoids antiviral inhibitors targeting 3C-like protease of porcine epidemic diarrhea virus. Front. Microbiol., 15.","DOI":"10.3389\/fmicb.2024.1357470"},{"key":"ref_147","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1016\/j.bbrc.2022.04.086","article-title":"Crystal structure of SARS-CoV 3C-like protease with baicalein","volume":"611","author":"Feng","year":"2022","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"ref_148","doi-asserted-by":"crossref","first-page":"100851","DOI":"10.1016\/j.phyplu.2025.100851","article-title":"Comprehensive insights into the therapeutic effects of baicalein and baicalin against SARS-COV-2 infection","volume":"5","author":"Lin","year":"2025","journal-title":"Phytomed. Plus"},{"key":"ref_149","doi-asserted-by":"crossref","first-page":"2268","DOI":"10.1038\/s41467-022-29915-z","article-title":"Covalent narlaprevir- and boceprevir-derived hybrid inhibitors of SARS-CoV-2 main protease","volume":"13","author":"Kneller","year":"2022","journal-title":"Nat. Commun."},{"key":"ref_150","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1021\/acsinfecdis.0c00761","article-title":"Boceprevir, Calpain Inhibitors II and XII, and GC-376 Have Broad-Spectrum Antiviral Activity against Coronaviruses","volume":"7","author":"Hu","year":"2021","journal-title":"ACS Infect. Dis."},{"key":"ref_151","doi-asserted-by":"crossref","unstructured":"Gammeltoft, K.A., Zhou, Y., Ryberg, L.A., Pham, L.V., Binderup, A., Hernandez, C.R.D., Offersgaard, A., Fahn\u00f8e, U., Peters, G.H.J., and Ramirez, S. (2023). Substitutions in SARS-CoV-2 Mpro Selected by Protease Inhibitor Boceprevir Confer Resistance to Nirmatrelvir. Viruses, 15.","DOI":"10.3390\/v15091970"},{"key":"ref_152","doi-asserted-by":"crossref","first-page":"2580","DOI":"10.1080\/14786419.2021.1904923","article-title":"Chlorogenic acid, a natural product as potential inhibitor of COVID-19: Virtual screening experiment based on network pharmacology and molecular docking","volume":"36","author":"Wang","year":"2022","journal-title":"Nat. Prod. Res."},{"key":"ref_153","doi-asserted-by":"crossref","first-page":"107671","DOI":"10.1016\/j.intimp.2021.107671","article-title":"Chlorogenic acid is a positive regulator of MDA5, TLR7 and NF-\u03baB signaling pathways mediated antiviral responses against Gammacoronavirus infection","volume":"96","author":"Abaidullah","year":"2021","journal-title":"Int. Immunopharmacol."},{"key":"ref_154","doi-asserted-by":"crossref","first-page":"111359","DOI":"10.1016\/j.intimp.2023.111359","article-title":"Chlorogenic acid inhibits porcine deltacoronavirus release by targeting apoptosis","volume":"127","author":"Shi","year":"2024","journal-title":"Int. Immunopharmacol."},{"key":"ref_155","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1080\/21691401.2023.2207606","article-title":"Antiviral and antibacterial potential of electrosprayed PVA\/PLGA nanoparticles loaded with chlorogenic acid for the management of coronavirus and Pseudomonas aeruginosa lung infection","volume":"51","author":"Saleh","year":"2023","journal-title":"Artif. Cells Nanomed. Biotechnol."},{"key":"ref_156","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1038\/s41594-020-0440-6","article-title":"Structural basis for the inhibition of SARS-CoV-2 main protease by antineoplastic drug carmofur","volume":"27","author":"Jin","year":"2020","journal-title":"Nat. Struct. Mol. Biol."},{"key":"ref_157","doi-asserted-by":"crossref","first-page":"150469","DOI":"10.1016\/j.bbrc.2024.150469","article-title":"Structural basis of main proteases of MERS-CoV bound to antineoplastic drug carmofur","volume":"735","author":"Guo","year":"2024","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"ref_158","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1021\/acsptsci.0c00130","article-title":"Ebselen, Disulfiram, Carmofur, PX-12, Tideglusib, and Shikonin Are Nonspecific Promiscuous SARS-CoV-2 Main Protease Inhibitors","volume":"3","author":"Ma","year":"2020","journal-title":"ACS Pharmacol. Transl. Sci."},{"key":"ref_159","doi-asserted-by":"crossref","unstructured":"Fukumoto, Y., Suzuki, N., Hara, R., Tanaka, Y.K., and Ogra, Y. (2024). Development of a Biosafety Level 1 Cellular Assay for Identifying Small-Molecule Antivirals Targeting the Main Protease of SARS-CoV-2: Evaluation of Cellular Activity of GC376, Boceprevir, Carmofur, Ebselen, and Selenoneine. Int. J. Mol. Sci., 25.","DOI":"10.3390\/ijms25115767"},{"key":"ref_160","doi-asserted-by":"crossref","first-page":"133955","DOI":"10.1016\/j.ijbiomac.2024.133955","article-title":"Disulfiram inhibits coronaviral main protease by conjugating to its substrate entry site","volume":"276","author":"Kuan","year":"2024","journal-title":"Int. J. Biol. Macromol."},{"key":"ref_161","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1021\/acsptsci.1c00022","article-title":"Synergistic Inhibition of SARS-CoV-2 Replication Using Disulfiram\/Ebselen and Remdesivir","volume":"4","author":"Chen","year":"2021","journal-title":"ACS Pharmacol. Transl. Sci."},{"key":"ref_162","doi-asserted-by":"crossref","unstructured":"Fillmore, N., Bell, S., Shen, C., Nguyen, V., La, J., Dubreuil, M., Strymish, J., Brophy, M., Mehta, G., and Wu, H. (2021). Disulfiram use is associated with lower risk of COVID-19: A retrospective cohort study. PLoS ONE, 16.","DOI":"10.1101\/2021.03.10.21253331"},{"key":"ref_163","doi-asserted-by":"crossref","first-page":"3061","DOI":"10.1038\/s41467-021-23313-7","article-title":"Inhibition mechanism of SARS-CoV-2 main protease by ebselen and its derivatives","volume":"12","author":"Amporndanai","year":"2021","journal-title":"Nat. Commun."},{"key":"ref_164","doi-asserted-by":"crossref","first-page":"3640","DOI":"10.1038\/s41598-021-83229-6","article-title":"Identification of ebselen and its analogues as potent covalent inhibitors of papain-like protease from SARS-CoV-2","volume":"11","author":"Tomczak","year":"2021","journal-title":"Sci. Rep."},{"key":"ref_165","doi-asserted-by":"crossref","unstructured":"Wildner, G., Tucci, A.R., Prestes, A.S., Muller, T., Rosa, A.D.S., Borba, N.R.R., Ferreira, V.N., Rocha, J.B.T., Miranda, M.D., and Barbosa, N.V. (2023). Ebselen and Diphenyl Diselenide Inhibit SARS-CoV-2 Replication at Non-Toxic Concentrations to Human Cell Lines. Vaccines, 11.","DOI":"10.3390\/vaccines11071222"},{"key":"ref_166","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.antiviral.2014.07.014","article-title":"Nitazoxanide: A first-in-class broad-spectrum antiviral agent","volume":"110","author":"Rossignol","year":"2014","journal-title":"Antivir. Res."},{"key":"ref_167","doi-asserted-by":"crossref","first-page":"11096","DOI":"10.1128\/JVI.01213-13","article-title":"Thiazolides, a new class of antiviral agents effective against rotavirus infection, target viral morphogenesis, inhibiting viroplasm formation","volume":"87","author":"Ciucci","year":"2013","journal-title":"J. Virol."},{"key":"ref_168","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1016\/j.isci.2019.07.003","article-title":"The FDA-Approved Oral Drug Nitazoxanide Amplifies Host Antiviral Responses and Inhibits Ebola Virus","volume":"19","author":"Jasenosky","year":"2019","journal-title":"iScience"},{"key":"ref_169","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.antiviral.2014.11.010","article-title":"A screen of the NIH Clinical Collection small molecule library identifies potential anti-coronavirus drugs","volume":"114","author":"Cao","year":"2015","journal-title":"Antivir. Res."},{"key":"ref_170","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/j.jiph.2016.04.001","article-title":"Nitazoxanide, a new drug candidate for the treatment of Middle East respiratory syndrome coronavirus","volume":"9","author":"Rossignol","year":"2016","journal-title":"J. Infect. Public Health"},{"key":"ref_171","doi-asserted-by":"crossref","first-page":"2003725","DOI":"10.1183\/13993003.03725-2020","article-title":"Early use of nitazoxanide in mild COVID-19 disease: Randomised, placebo-controlled trial","volume":"58","author":"Rocco","year":"2021","journal-title":"Eur. Respir. J."},{"key":"ref_172","doi-asserted-by":"crossref","first-page":"109765","DOI":"10.1016\/j.mehy.2020.109765","article-title":"Plausible mechanisms of Niclosamide as an antiviral agent against COVID-19","volume":"140","author":"Pindiprolu","year":"2020","journal-title":"Med. Hypotheses"},{"key":"ref_173","doi-asserted-by":"crossref","unstructured":"Mostafa, A., Kandeil, A., Elshaier, Y.A.M.M., Kutkat, O., Moatasim, Y., Rashad, A.A., Shehata, M., Gomaa, M.R., Mahrous, N., and Mahmoud, S.H. (2020). FDA-Approved Drugs with Potent In Vitro Antiviral Activity against Severe Acute Respiratory Syndrome Coronavirus 2. Pharmaceuticals, 13.","DOI":"10.3390\/ph13120443"},{"key":"ref_174","doi-asserted-by":"crossref","first-page":"2693","DOI":"10.1128\/AAC.48.7.2693-2696.2004","article-title":"Inhibition of severe acute respiratory syndrome coronavirus replication by niclosamide","volume":"48","author":"Wu","year":"2004","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_175","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1016\/j.virs.2023.01.008","article-title":"Identification of niclosamide as a novel antiviral agent against porcine epidemic diarrhea virus infection by targeting viral internalization","volume":"38","author":"Wang","year":"2023","journal-title":"Virol. Sin."},{"key":"ref_176","doi-asserted-by":"crossref","unstructured":"Brunaugh, A.D., Seo, H., Warnken, Z., Ding, L., Seo, S.H., and Smyth, H.D.C. (2021). Development and evaluation of inhalable composite niclosamide-lysozyme particles: A broad-spectrum, patient-adaptable treatment for coronavirus infections and sequalae. PLoS ONE, 16.","DOI":"10.1371\/journal.pone.0246803"},{"key":"ref_177","doi-asserted-by":"crossref","first-page":"108615","DOI":"10.1016\/j.clim.2020.108615","article-title":"An enlightening role for cytokine storm in coronavirus infection","volume":"222","author":"Zhao","year":"2021","journal-title":"Clin. Immunol."},{"key":"ref_178","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1002\/jmv.26232","article-title":"The cytokine storm and COVID-19","volume":"93","author":"Hu","year":"2021","journal-title":"J. Med. Virol."},{"key":"ref_179","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1016\/S0140-6736(20)30628-0","article-title":"COVID-19: Consider cytokine storm syndromes and immunosuppression","volume":"395","author":"Mehta","year":"2020","journal-title":"Lancet"},{"key":"ref_180","doi-asserted-by":"crossref","first-page":"10970","DOI":"10.1073\/pnas.2005615117","article-title":"Effective treatment of severe COVID-19 patients with tocilizumab","volume":"117","author":"Xu","year":"2020","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_181","doi-asserted-by":"crossref","unstructured":"Pelaia, C., Calabrese, C., Garofalo, E., Bruni, A., Vatrella, A., and Pelaia, G. (2021). Therapeutic Role of Tocilizumab in SARS-CoV-2-Induced Cytokine Storm: Rationale and Current Evidence. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms22063059"},{"key":"ref_182","doi-asserted-by":"crossref","first-page":"e445","DOI":"10.1093\/cid\/ciaa954","article-title":"Tocilizumab for Treatment of Mechanically Ventilated Patients With COVID-19","volume":"73","author":"Somers","year":"2021","journal-title":"Clin. Infect. Dis."},{"key":"ref_183","doi-asserted-by":"crossref","first-page":"n84","DOI":"10.1136\/bmj.n84","article-title":"Effect of tocilizumab on clinical outcomes at 15 days in patients with severe or critical coronavirus disease 2019: Randomised controlled trial","volume":"372","author":"Veiga","year":"2021","journal-title":"BMJ"},{"key":"ref_184","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1056\/NEJMoa2028700","article-title":"Tocilizumab in Hospitalized Patients with Severe COVID-19 Pneumonia","volume":"384","author":"Rosas","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_185","first-page":"2134","article-title":"Treating rheumatological diseases and co-morbidities with interleukin-1 blocking therapies","volume":"54","author":"Cavalli","year":"2015","journal-title":"Rheumatology"},{"key":"ref_186","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1038\/s41591-018-0041-7","article-title":"CAR T cell-induced cytokine release syndrome is mediated by macrophages and abated by IL-1 blockade","volume":"24","author":"Giavridis","year":"2018","journal-title":"Nat. Med."},{"key":"ref_187","doi-asserted-by":"crossref","first-page":"1752","DOI":"10.1038\/s41591-021-01499-z","article-title":"Early treatment of COVID-19 with anakinra guided by soluble urokinase plasminogen receptor plasma levels: A double-blind, randomized controlled phase 3 trial","volume":"27","author":"Kyriazopoulou","year":"2021","journal-title":"Nat. Med."},{"key":"ref_188","doi-asserted-by":"crossref","first-page":"e393","DOI":"10.1016\/S2665-9913(20)30164-8","article-title":"Anakinra for severe forms of COVID-19: A cohort study","volume":"2","author":"Huet","year":"2020","journal-title":"Lancet Rheumatol."},{"key":"ref_189","doi-asserted-by":"crossref","first-page":"2208872","DOI":"10.1080\/07853890.2023.2208872","article-title":"Clinical efficacy and safety of interleukin-1 blockade in the treatment of patients with COVID-19: A systematic review and meta-analysis of randomized controlled trials","volume":"55","author":"Lan","year":"2023","journal-title":"Ann. Med."},{"key":"ref_190","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/0014-2999(96)00254-3","article-title":"Interactions of selective serotonin reuptake inhibitors with subtypes of sigma receptors in rat brain","volume":"307","author":"Narita","year":"1996","journal-title":"Eur. J. Pharmacol."},{"key":"ref_191","doi-asserted-by":"crossref","first-page":"1898","DOI":"10.1038\/s41380-021-01432-3","article-title":"Mechanisms of action of fluvoxamine for COVID-19: A historical review","volume":"27","author":"Hashimoto","year":"2022","journal-title":"Mol. Psychiatry"},{"key":"ref_192","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1007\/s00406-021-01326-z","article-title":"Old drug fluvoxamine, new hope for COVID-19","volume":"272","author":"Hashimoto","year":"2022","journal-title":"Eur. Arch. Psychiatry Clin. Neurosci."},{"key":"ref_193","doi-asserted-by":"crossref","unstructured":"Sukhatme, V.P., Reiersen, A.M., Vayttaden, S.J., and Sukhatme, V.V. (2021). Fluvoxamine: A Review of Its Mechanism of Action and Its Role in COVID-19. Front. Pharmacol., 12.","DOI":"10.3389\/fphar.2021.652688"},{"key":"ref_194","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1038\/s41380-021-01309-5","article-title":"The acid sphingomyelinase\/ceramide system in COVID-19","volume":"27","author":"Kornhuber","year":"2022","journal-title":"Mol. Psychiatry"},{"key":"ref_195","doi-asserted-by":"crossref","first-page":"2292","DOI":"10.1001\/jama.2020.22760","article-title":"Fluvoxamine vs Placebo and Clinical Deterioration in Outpatients With Symptomatic COVID-19: A Randomized Clinical Trial","volume":"324","author":"Lenze","year":"2020","journal-title":"Jama"},{"key":"ref_196","doi-asserted-by":"crossref","first-page":"e42","DOI":"10.1016\/S2214-109X(21)00448-4","article-title":"Effect of early treatment with fluvoxamine on risk of emergency care and hospitalisation among patients with COVID-19: The TOGETHER randomised, platform clinical trial","volume":"10","author":"Reis","year":"2022","journal-title":"Lancet Glob. Health"},{"key":"ref_197","doi-asserted-by":"crossref","unstructured":"Zhou, Q., Zhao, G., Pan, Y., Zhang, Y., and Ni, Y. (2024). The efficacy and safety of fluvoxamine in patients with COVID-19: A systematic review and meta-analysis from randomized controlled trials. PLoS ONE, 19.","DOI":"10.1371\/journal.pone.0300512"},{"key":"ref_198","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1056\/NEJMoa2201662","article-title":"Randomized Trial of Metformin, Ivermectin, and Fluvoxamine for COVID-19","volume":"387","author":"Bramante","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"ref_199","doi-asserted-by":"crossref","first-page":"ofad419","DOI":"10.1093\/ofid\/ofad419","article-title":"The STOP COVID 2 Study: Fluvoxamine vs Placebo for Outpatients With Symptomatic COVID-19, a Fully Remote Randomized Controlled Trial","volume":"10","author":"Reiersen","year":"2023","journal-title":"Open Forum Infect. Dis."},{"key":"ref_200","doi-asserted-by":"crossref","first-page":"e30","DOI":"10.1016\/S0140-6736(20)30304-4","article-title":"Baricitinib as potential treatment for 2019-nCoV acute respiratory disease","volume":"395","author":"Richardson","year":"2020","journal-title":"Lancet"},{"key":"ref_201","doi-asserted-by":"crossref","first-page":"106749","DOI":"10.1016\/j.intimp.2020.106749","article-title":"Baricitinib, a drug with potential effect to prevent SARS-COV-2 from entering target cells and control cytokine storm induced by COVID-19","volume":"86","author":"Zhang","year":"2020","journal-title":"Int. Immunopharmacol."},{"key":"ref_202","doi-asserted-by":"crossref","first-page":"1523","DOI":"10.1002\/jmv.27482","article-title":"Clinical efficacy and adverse events of baricitinib treatment for coronavirus disease-2019 (COVID-19): A systematic review and meta-analysis","volume":"94","author":"Lin","year":"2022","journal-title":"J. Med. Virol."},{"key":"ref_203","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1002\/phar.2438","article-title":"Baricitinib: A Review of Pharmacology, Safety, and Emerging Clinical Experience in COVID-19","volume":"40","author":"Jorgensen","year":"2020","journal-title":"Pharmacotherapy"},{"key":"ref_204","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1016\/S2213-2600(21)00331-3","article-title":"Efficacy and safety of baricitinib for the treatment of hospitalised adults with COVID-19 (COV-BARRIER): A randomised, double-blind, parallel-group, placebo-controlled phase 3 trial","volume":"9","author":"Marconi","year":"2021","journal-title":"Lancet Respir. Med."},{"key":"ref_205","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1007\/s15010-021-01730-6","article-title":"Baricitinib combination therapy: A narrative review of repurposed Janus kinase inhibitor against severe SARS-CoV-2 infection","volume":"50","author":"Torabi","year":"2022","journal-title":"Infection"},{"key":"ref_206","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1056\/NEJMoa2021436","article-title":"Dexamethasone in Hospitalized Patients with COVID-19","volume":"384","author":"Horby","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_207","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1001\/jama.2020.17021","article-title":"Effect of Dexamethasone on Days Alive and Ventilator-Free in Patients With Moderate or Severe Acute Respiratory Distress Syndrome and COVID-19: The CoDEX Randomized Clinical Trial","volume":"324","author":"Tomazini","year":"2020","journal-title":"Jama"},{"key":"ref_208","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1038\/s41591-021-01576-3","article-title":"Dexamethasone modulates immature neutrophils and interferon programming in severe COVID-19","volume":"28","author":"Sinha","year":"2022","journal-title":"Nat. Med."},{"key":"ref_209","doi-asserted-by":"crossref","first-page":"173854","DOI":"10.1016\/j.ejphar.2021.173854","article-title":"Dexamethasone: Therapeutic potential, risks, and future projection during COVID-19 pandemic","volume":"894","author":"Noreen","year":"2021","journal-title":"Eur. J. Pharmacol."},{"key":"ref_210","doi-asserted-by":"crossref","first-page":"13681","DOI":"10.1128\/JVI.01702-07","article-title":"Altered pathogenesis of porcine respiratory coronavirus in pigs due to immunosuppressive effects of dexamethasone: Implications for corticosteroid use in treatment of severe acute respiratory syndrome coronavirus","volume":"81","author":"Jung","year":"2007","journal-title":"J. Virol."},{"key":"ref_211","doi-asserted-by":"crossref","unstructured":"Dai, J., Wang, H., Liao, Y., Tan, L., Sun, Y., Song, C., Liu, W., Ding, C., Luo, T., and Qiu, X. (2022). Non-Targeted Metabolomic Analysis of Chicken Kidneys in Response to Coronavirus IBV Infection Under Stress Induced by Dexamethasone. Front. Cell Infect. Microbiol., 12.","DOI":"10.3389\/fcimb.2022.945865"},{"key":"ref_212","doi-asserted-by":"crossref","first-page":"E1","DOI":"10.1152\/ajpendo.90926.2008","article-title":"Acyl-coenzyme A:cholesterol acyltransferases","volume":"297","author":"Chang","year":"2009","journal-title":"Am. J. Physiol. Endocrinol. Metab."},{"key":"ref_213","doi-asserted-by":"crossref","first-page":"1933","DOI":"10.1016\/j.csbj.2021.04.001","article-title":"Dependence of SARS-CoV-2 infection on cholesterol-rich lipid raft and endosomal acidification","volume":"19","author":"Li","year":"2021","journal-title":"Comput. Struct. Biotechnol. J."},{"key":"ref_214","doi-asserted-by":"crossref","first-page":"e202302453","DOI":"10.26508\/lsa.202302453","article-title":"Cholesterol and COVID-19-therapeutic opportunities at the host\/virus interface during cell entry","volume":"7","author":"Grewal","year":"2024","journal-title":"Life Sci. Alliance"},{"key":"ref_215","doi-asserted-by":"crossref","first-page":"1481087","DOI":"10.1155\/tbed\/1481087","article-title":"Discovery of Cetaben as a Novel Antiviral Agent Against Porcine Epidemic Diarrhea Virus From a Cholesterol-Lowering Compound Library","volume":"2026","author":"Li","year":"2026","journal-title":"Transbound. Emerg. Dis."},{"key":"ref_216","doi-asserted-by":"crossref","unstructured":"Wing, P.A.C., Schmidt, N.M., Peters, R., Erdmann, M., Brown, R., Wang, H., Swadling, L., Newman, J., Thakur, N., and Shionoya, K. (2023). An ACAT inhibitor suppresses SARS-CoV-2 replication and boosts antiviral T cell activity. PLoS Pathog., 19.","DOI":"10.1371\/journal.ppat.1011323"},{"key":"ref_217","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1038\/s41392-023-01510-8","article-title":"Metabolic alterations upon SARS-CoV-2 infection and potential therapeutic targets against coronavirus infection","volume":"8","author":"Chen","year":"2023","journal-title":"Signal Transduct. Target. Ther."},{"key":"ref_218","doi-asserted-by":"crossref","first-page":"107170","DOI":"10.1016\/j.phrs.2024.107170","article-title":"SARS-CoV-2 mitochondrial metabolic and epigenomic reprogramming in COVID-19","volume":"204","author":"Guarnieri","year":"2024","journal-title":"Pharmacol. Res."},{"key":"ref_219","doi-asserted-by":"crossref","first-page":"108063","DOI":"10.1016\/j.jbc.2024.108063","article-title":"Glutamine metabolism is essential for coronavirus replication in host cells and in mice","volume":"301","author":"Greene","year":"2025","journal-title":"J. Biol. Chem."},{"key":"ref_220","doi-asserted-by":"crossref","first-page":"1270","DOI":"10.1021\/bi952168g","article-title":"The immunosuppressive metabolite of leflunomide is a potent inhibitor of human dihydroorotate dehydrogenase","volume":"35","author":"Davis","year":"1996","journal-title":"Biochemistry"},{"key":"ref_221","doi-asserted-by":"crossref","first-page":"107398","DOI":"10.1016\/j.intimp.2021.107398","article-title":"Leflunomide an immunomodulator with antineoplastic and antiviral potentials but drug-induced liver injury: A comprehensive review","volume":"93","author":"Alamri","year":"2021","journal-title":"Int. Immunopharmacol."},{"key":"ref_222","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.virol.2020.06.009","article-title":"Inhibition of porcine epidemic diarrhea virus (PEDV) replication by A77 1726 through targeting JAK and Src tyrosine kinases","volume":"551","author":"Li","year":"2020","journal-title":"Virology"},{"key":"ref_223","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1007\/s13238-020-00768-w","article-title":"Novel and potent inhibitors targeting DHODH are broad-spectrum antivirals against RNA viruses including newly-emerged coronavirus SARS-CoV-2","volume":"11","author":"Xiong","year":"2020","journal-title":"Protein Cell"},{"key":"ref_224","first-page":"101395","article-title":"In vitro evaluation of the activity of teriflunomide against SARS-CoV-2 and the human coronaviruses 229E and OC43","volume":"33","author":"Lang","year":"2023","journal-title":"Biochem. Biophys. Rep."},{"key":"ref_225","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1007\/s12250-020-00258-7","article-title":"A Small-Scale Medication of Leflunomide as a Treatment of COVID-19 in an Open-Label Blank-Controlled Clinical Trial","volume":"35","author":"Hu","year":"2020","journal-title":"Virol. Sin."},{"key":"ref_226","doi-asserted-by":"crossref","unstructured":"Pan, Z., Wan, Z., Wang, Y., Zha, S., Zhang, J., Chen, H., and Hu, K. (2023). An open-label randomized controlled trial of leflunomide in patients with acute SARS-CoV-2 omicron variant infection. Front. Med., 10.","DOI":"10.3389\/fmed.2023.1218102"},{"key":"ref_227","doi-asserted-by":"crossref","first-page":"268","DOI":"10.4062\/biomolther.2021.032","article-title":"Antiviral Efficacy of Pralatrexate against SARS-CoV-2","volume":"29","author":"Bae","year":"2021","journal-title":"Biomol. Ther."},{"key":"ref_228","doi-asserted-by":"crossref","unstructured":"Iaconis, D., Caccuri, F., Manelfi, C., Talarico, C., Bugatti, A., Filippini, F., Zani, A., Novelli, R., Kuzikov, M., and Ellinger, B. (2023). DHFR Inhibitors Display a Pleiotropic Anti-Viral Activity against SARS-CoV-2: Insights into the Mechanisms of Action. Viruses, 15.","DOI":"10.20944\/preprints202304.0082.v1"},{"key":"ref_229","doi-asserted-by":"crossref","unstructured":"Zhang, H., Yang, Y., Li, J., Wang, M., Saravanan, K.M., Wei, J., Tze-Yang Ng, J., Tofazzal Hossain, M., Liu, M., and Zhang, H. (2020). A novel virtual screening procedure identifies Pralatrexate as inhibitor of SARS-CoV-2 RdRp and it reduces viral replication in vitro. PLoS Comput. Biol., 16.","DOI":"10.1371\/journal.pcbi.1008489"},{"key":"ref_230","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1200\/JCO.2010.29.9024","article-title":"Pralatrexate in patients with relapsed or refractory peripheral T-cell lymphoma: Results from the pivotal PROPEL study","volume":"29","author":"Pro","year":"2011","journal-title":"J. Clin. Oncol."},{"key":"ref_231","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1038\/s41574-023-00833-4","article-title":"Metformin: Update on mechanisms of action and repurposing potential","volume":"19","author":"Foretz","year":"2023","journal-title":"Nat. Rev. Endocrinol."},{"key":"ref_232","doi-asserted-by":"crossref","unstructured":"Chen, X., Guo, H., Qiu, L., Zhang, C., Deng, Q., and Leng, Q. (2020). Immunomodulatory and Antiviral Activity of Metformin and Its Potential Implications in Treating Coronavirus Disease 2019 and Lung Injury. Front. Immunol., 11.","DOI":"10.3389\/fimmu.2020.02056"},{"key":"ref_233","doi-asserted-by":"crossref","first-page":"199010","DOI":"10.1016\/j.virusres.2022.199010","article-title":"Metformin suppresses SARS-CoV-2 in cell culture","volume":"323","author":"Parthasarathy","year":"2023","journal-title":"Virus Res."},{"key":"ref_234","doi-asserted-by":"crossref","first-page":"988","DOI":"10.1016\/j.jia.2023.10.010","article-title":"Porcine enteric alphacoronavirus infection increases lipid droplet accumulation to facilitate the virus replication","volume":"23","author":"Gao","year":"2024","journal-title":"J. Integr. Agric."},{"key":"ref_235","doi-asserted-by":"crossref","first-page":"109282","DOI":"10.1016\/j.cbi.2020.109282","article-title":"Rapamycin as a potential repurpose drug candidate for the treatment of COVID-19","volume":"331","author":"Husain","year":"2020","journal-title":"Chem. Biol. Interact."},{"key":"ref_236","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1016\/j.drudis.2021.11.002","article-title":"The PI3K\/Akt\/mTOR pathway: A potential pharmacological target in COVID-19","volume":"27","author":"Basile","year":"2022","journal-title":"Drug Discov. Today"},{"key":"ref_237","doi-asserted-by":"crossref","first-page":"e160766","DOI":"10.1172\/JCI160766","article-title":"Rapalogs downmodulate intrinsic immunity and promote cell entry of SARS-CoV-2","volume":"132","author":"Shi","year":"2022","journal-title":"J. Clin. Investig."},{"key":"ref_238","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1128\/AAC.03659-14","article-title":"Antiviral potential of ERK\/MAPK and PI3K\/AKT\/mTOR signaling modulation for Middle East respiratory syndrome coronavirus infection as identified by temporal kinome analysis","volume":"59","author":"Kindrachuk","year":"2015","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_239","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.1002\/jmv.26009","article-title":"Immunoregulation with mTOR inhibitors to prevent COVID-19 severity: A novel intervention strategy beyond vaccines and specific antiviral medicines","volume":"92","author":"Zheng","year":"2020","journal-title":"J. Med. Virol."},{"key":"ref_240","doi-asserted-by":"crossref","unstructured":"Perkins, G.B., Tunbridge, M.J., Chai, C.S., Hope, C.M., Yeow, A.E.L., Salehi, T., Singer, J., Shi, B., Masavuli, M.G., and Mekonnen, Z.A. (2023). mTOR inhibition improves the formation of functional T cell memory following COVID-19 vaccination of kidney transplant recipients. medRxiv.","DOI":"10.1101\/2023.03.27.23287773"},{"key":"ref_241","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.antiviral.2017.08.010","article-title":"Rapamycin-induced autophagy restricts porcine epidemic diarrhea virus infectivity in porcine intestinal epithelial cells","volume":"146","author":"Ko","year":"2017","journal-title":"Antivir. Res."},{"key":"ref_242","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1124\/dmd.121.000774","article-title":"Comparison of Tissue Abundance of Non-Cytochrome P450 Drug-Metabolizing Enzymes by Quantitative Proteomics between Humans and Laboratory Animal Species","volume":"50","author":"Basit","year":"2022","journal-title":"Drug Metab. Dispos."},{"key":"ref_243","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1016\/S0090-9556(25)06742-X","article-title":"Species similarities and differences in pharmacokinetics","volume":"23","author":"Lin","year":"1995","journal-title":"Drug Metab. Dispos."},{"key":"ref_244","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1007\/978-3-642-10324-7_2","article-title":"Species differences in pharmacokinetics and pharmacodynamics","volume":"199","author":"Toutain","year":"2010","journal-title":"Handb. Exp. Pharmacol."},{"key":"ref_245","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1517\/17425255.2.6.875","article-title":"Species differences between mouse, rat, dog, monkey and human CYP-mediated drug metabolism, inhibition and induction","volume":"2","author":"Martignoni","year":"2006","journal-title":"Expert. Opin. Drug Metab. Toxicol."},{"key":"ref_246","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1124\/dmd.121.000801","article-title":"Disposition of Nirmatrelvir, an Orally Bioavailable Inhibitor of SARS-CoV-2 3C-Like Protease, across Animals and Humans","volume":"50","author":"Eng","year":"2022","journal-title":"Drug Metab. Dispos."},{"key":"ref_247","doi-asserted-by":"crossref","first-page":"e2407766","DOI":"10.1002\/advs.202407766","article-title":"The S2 Pocket Governs the Genus-Specific Substrate Selectivity of Coronavirus 3C-Like Protease","volume":"11","author":"Zhou","year":"2024","journal-title":"Adv. Sci."},{"key":"ref_248","doi-asserted-by":"crossref","unstructured":"Lu, J., Chen, S.A., Khan, M.B., Brassard, R., Arutyunova, E., Lamer, T., Vuong, W., Fischer, C., Young, H.S., and Vederas, J.C. (2022). Crystallization of Feline Coronavirus Mpro With GC376 Reveals Mechanism of Inhibition. Front. Chem., 10.","DOI":"10.3389\/fchem.2022.852210"},{"key":"ref_249","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/nrd.2018.92","article-title":"Overcoming the legal and regulatory barriers to drug repurposing","volume":"18","author":"Breckenridge","year":"2019","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_250","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1002\/cpt.3732","article-title":"An Integrated AI-PBPK Platform for Predicting Drug In Vivo Fate and Tissue Distribution in Human and Inter-Species Extrapolation","volume":"118","author":"Wang","year":"2025","journal-title":"Clin. Pharmacol. Ther."},{"key":"ref_251","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1038\/s41467-024-54615-1","article-title":"Human ACE2 transgenic pigs are susceptible to SARS-CoV-2 and develop COVID-19-like disease","volume":"16","author":"Chau","year":"2025","journal-title":"Nat. Commun."}],"container-title":["Viruses"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1999-4915\/18\/7\/804\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T04:29:46Z","timestamp":1784780986000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1999-4915\/18\/7\/804"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,21]]},"references-count":251,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2026,7]]}},"alternative-id":["v18070804"],"URL":"https:\/\/doi.org\/10.3390\/v18070804","relation":{},"ISSN":["1999-4915"],"issn-type":[{"value":"1999-4915","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,21]]}}}